James Jordan on Where Clinical Strategy Meets Market Reality

In this episode, Julio Martinez-Clark asks James F. Jordan whether medtech companies should still look to Europe first, and what that choice means for Latin America. Jordan, who was President & CEO of Pittsburgh Life Sciences Greenhouse and a professor at Carnegie Mellon University when the episode was recorded, does not answer with a simple yes or no. He breaks the problem into two different questions: where a company should gather early clinical evidence, and where it should expect to build a business.

That split is the useful part of the conversation. Founders often talk about regulatory access, physician enthusiasm, reimbursement, investor expectations, and exit value as if they move together. Jordan argues that they do not. If you separate them, the Europe-versus-U.S.-versus-Latin America debate becomes much clearer.

Clinical evidence and commercialization are not the same decision

Jordan's first point is that Europe and Latin America can both be attractive places to gather early data. He says the FDA accepts data from certain countries for early filings, which makes overseas studies relevant to a U.S. path. In that sense, a founder can rationally look outside the U.S. for first-in-man work.

But he warns against turning that clinical logic into a commercial assumption. Europe may look unified from far away, yet adoption still happens country by country. Regulatory clearance is only one hurdle. Reimbursement, hospital purchasing, and sales execution still vary by market. Jordan even notes that some countries move much more slowly than others, specifically mentioning France, the UK, and Italy as slower environments.

That distinction matters because startups are usually short on both time and capital. A favorable place to run a study is not automatically a favorable place to build a sales organization. Jordan's frame helps founders avoid a common mistake: confusing a good evidence strategy with a good go-to-market strategy.

Investors care about more than approvals

Jordan then shifts the lens from regulators to capital. In his view, startup strategy has to satisfy three audiences at once: "You have three constituencies in a startup. You have the customer themselves who you eventually sell to. You have the investors and you have the acquirers."

That quote explains why a Europe-first commercial plan can look weaker in a boardroom than it does in a regulatory slide deck. Jordan says many venture investors have not seen enough proof that a Europe-only or Latin America-only commercial strategy meaningfully speeds market entry or produces meaningful post-approval revenue. His summary is blunt: "Very few investors have found that they have either materially reduced their time to market or materially increased post-approval revenue by having a European or a Latin America only strategy."

This does not mean international work lacks value. It means the value has to be defined correctly. Early data can reduce technical uncertainty. It can validate physician demand. It can support the next financing step. But if the founder presents Europe as if it will quickly become a large revenue engine, Jordan suggests investors may push back.

That is a practical lesson for pitch preparation. When founders describe their geographic plan, they should say which part is about evidence generation, which part is about commercial scale, and which part is about eventual exit value. Lumping those together can make the strategy sound broader than it really is.

Latin America's strongest early advantage is relationship-building

Jordan applies similar logic to Latin America. He says Brazil and Argentina were once especially attractive because of physician quality and lower regulatory barriers, but he also argues those markets have become more like the U.S. in their requirements. Even so, he still sees a meaningful role for the region in early clinical work.

The reason goes beyond cost or speed. Jordan says landmark trials create durable professional ties among physicians, institutions, and global companies. Those ties can outlast the startup phase and shape how expertise flows later. His simplest version of that idea is memorable: "companies will never forget the people that did their clinical."

That point becomes even more important when a country is trying to build a reputation, not just win a single study. Jordan tells Julio Martinez-Clark that physicians who participate in landmark trials can become visible at major trade shows and later help train peers from other countries, including the U.S. In his telling, clinical trial participation is not only a service business. It is also a brand-building mechanism for a national medical community.

For Latin American policymakers and hospital leaders, that is the most concrete takeaway from the episode. If the goal is to bring advanced technologies into the country earlier, the first win may be clinical participation, not immediate commercialization.

Global approvals can matter more at exit than at launch

Jordan's most nuanced point may be his last one: international approvals can become more valuable as a company matures. He says that once a startup is commercializing in the U.S. and thinking about how long it will remain independent, approvals in Europe and Latin America can add to exit value.

Why? Because an acquirer inherits those approvals. Jordan gives an example from his Boston Scientific experience to show how a startup's existing approval in another market can lower the cost and friction of entry for a larger buyer. In other words, a geography that may not have driven early revenue can still make the company more attractive in an acquisition.

That is an important correction to the usual either-or debate. Jordan is not saying founders should ignore Europe or Latin America. He is saying they should sequence them properly. Early on, these markets may be most useful for data and relationships. Later, they may strengthen strategic positioning and acquisition appeal.

Listen to the episode

The conversation is short, but it gives founders a disciplined way to think about geography: separate evidence from revenue, and separate launch plans from exit plans. If you want to hear how James F. Jordan and Julio Martinez-Clark frame Europe, Latin America, investors, and acquirers in Jordan's own words, listen to the full episode here.

About Global Trial Accelerators™

Global Trial Accelerators™ is the podcast for MedTech, Biopharma and Radiopharma founders navigating first-in-human clinical trials. It is hosted by Jesús E. Moreno and produced by bioaccess®, a CRO purpose-built for first-in-human trials across the Americas.